NCCN 2018 Congress Series Live Webinars: Acute Leukemia

During 2017 the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010. Progress in acute lymphoblastic leukemia (ALL) also leaped forward during 2017, with FDA approval of tisagenlecleucel, the first-ever chimeric antigen receptor (CAR) T cell therapy for patients with relapsed or refractory disease. While a cure for all acute leukemias remains elusive, great progress is being made. Clinicians need to be aware that recommendations for initiating, combining, and sequencing treatments are rapidly changing, along with guidelines for avoiding or managing adverse effects. All members of the oncology care team, and their patients, need a deeper understanding of the efficacy, safety, and side effect profiles of these novel agents.

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with acute leukemia.

Additional information

This activity is supported by educational grants from:  

  • Astellas
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Novartis Pharmaceuticals

Supported by an independent educational grant from AbbVie.

Supported by educational funding provided by Amgen.

This educational activity is supported by an independent medical educational grant from Shire.

Course summary
Course opens: 
Course expires: 

Refractory Acute Lymphoblastic Leukemia Management: New Insights
Tuesday, October 9, 2018 • 11:00 AM - 12:00 PM EDT
Bijal Shah, MD, Moffitt Cancer Center

Advances in Acute Myeloid Leukemia Management in Older Adults: Impact on Practice
Friday, November 2, 2018 • 12:00 - 1:00 PM EDT
Daniel A. Pollyea, MD, MS, University of Colorado Cancer Center

Impact of Changing Molecular Landscape on Leukemia Management
Thursday, November 8, 2018 • 1:00 - 2:00 PM EST
Alice Mims, MD, The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute

Monitoring Minimal Residual Disease in Leukemia and Impact on Treatment
Thursday, November 29, 2018 • 1:00 - 2:00 PM EST
Bhavana Bhatnagar, DO, The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute



Access to participate in selected sessions is through the NCCN WebEx Site on the day of each scheduled program.

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

This program has been approved for AMA PRA Category 1 Credit™ and ABIM and ABPath MOC points for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual activity.

Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.


Please login or register to take this course.

Please refer to the Schedule tab for dates and times.  Check the webinars you would like to attend and click Enroll.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing